

Wenju Chang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7746867/publications.pdf>

Version: 2024-02-01

46
papers

803
citations

687363

13
h-index

552781

26
g-index

48
all docs

48
docs citations

48
times ranked

1371
citing authors

#	ARTICLE	IF	CITATIONS
1	HER2 positivity as a biomarker for poor prognosis and unresponsiveness to anti-EGFR therapy in colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 993-1002.	2.5	10
2	Association of RAS/BRAF Status and Prognosis of Metastatic Colorectal Cancer: Analysis of 1002 Consecutive Cases. <i>Annals of Surgical Oncology</i> , 2022, 29, 3593-3603.	1.5	3
3	miR-31-5p axis as a novel biomarker for predicting the development and prognosis of sporadic early-onset colorectal cancer. <i>Oncology Letters</i> , 2022, 23, 157.	1.8	6
4	Activation of miR-500a-3p/CDK6 axis suppresses aerobic glycolysis and colorectal cancer progression. <i>Journal of Translational Medicine</i> , 2022, 20, 106.	4.4	9
5	Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi-Center Retrospective Study. <i>Frontiers in Oncology</i> , 2022, 12, 838870.	2.8	4
6	Regorafenib in refractory metastatic colorectal cancer: A multi-center retrospective study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e15580-e15580.	1.6	0
7	The effect of non-curative endoscopic resection on cT1N0M0 colorectal carcinoma patients who underwent additional surgery. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 2862-2869.	2.4	5
8	Efficacy of conversion therapy on initially unresectable locally advanced rectal cancer. <i>Journal of Cancer</i> , 2021, 12, 4418-4423.	2.5	1
9	Short-Term and Long-Term Outcomes in Mid and Low Rectal Cancer With Robotic Surgery. <i>Frontiers in Oncology</i> , 2021, 11, 603073.	2.8	2
10	Multi-cancer detection and tissue of origin determination based on 5-hydroxymethylcytosine biomarkers in circulating cell-free DNA.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3123-3123.	1.6	1
11	The Combination of Neoadjuvant Therapy and Surgical Resection: A Safe and Effective Treatment for Rectal Gastrointestinal Stromal Tumors. <i>Cancer Management and Research</i> , 2021, Volume 13, 4671-4678.	1.9	2
12	Comparison between robotic natural orifice specimen extraction surgery and traditional laparoscopic low anterior resection for middle and low rectal cancer: A propensity score matching analysis. <i>Journal of Surgical Oncology</i> , 2021, 124, 607-618.	1.7	9
13	Preoperative Hepatic and Regional Arterial Chemotherapy in Patients Who Underwent Curative Colorectal Cancer Resection. <i>Annals of Surgery</i> , 2021, 273, 1066-1075.	4.2	8
14	Anatomical Resection Improves Disease-Free Survival After Lung Metastasectomy of Colorectal Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 9429-9437.	1.9	2
15	Short-term and long-term outcomes of robotic rectal surgery from the real word data of 1145 consecutive cases in China. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2020, 34, 4079-4088.	2.4	15
16	A trinity technique for prevention of low rectal anastomotic leakage in the robotic era. <i>European Journal of Surgical Oncology</i> , 2020, 46, e47-e54.	1.0	4
17	A novel patient-derived organoids-based xenografts model for preclinical drug response testing in patients with colorectal liver metastases. <i>Journal of Translational Medicine</i> , 2020, 18, 234.	4.4	14
18	Comprehensive Evaluation of Relapse Risk (CERR) Score for Colorectal Liver Metastases: Development and Validation. <i>Oncologist</i> , 2020, 25, e1031-e1041.	3.7	28

#	ARTICLE	IF	CITATIONS
19	Hormonal Suppression of Stem Cells Inhibits Symmetric Cell Division and Gastric Tumorigenesis. <i>Cell Stem Cell</i> , 2020, 26, 739-754.e8.	11.1	33
20	High MICB expression as a biomarker for good prognosis of colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1405-1413.	2.5	11
21	<p>Predictive And Prognostic Value Of Hepatic Steatosis In Conversion Therapy For Colorectal Liver-limited Metastases: A Propensity Score Matching Analysis</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 8315-8326.	1.9	2
22	Tumor-associated Macrophages as Prognostic and Predictive Biomarkers for Postoperative Adjuvant Chemotherapy in Patients with Stage II Colon Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3896-3907.	7.0	104
23	Comparison of HER2 overexpression with total <i>Her2</i> mutation on resistance of EGFR-targeted therapy in <i>Ras</i> wild-type mCRC patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3594-3594.	1.6	0
24	CCR7 high expression leads to cetuximab resistance by cross-talking with EGFR pathway in PI3K/AKT signals in colorectal cancer. <i>American Journal of Cancer Research</i> , 2019, 9, 2531-2543.	1.4	9
25	Imaging Tiny Hepatic Tumor Xenografts via Endoglin-Targeted Paramagnetic/Optical Nanoprobe. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 17047-17057.	8.0	30
26	Additional Biomarkers beyond RAS That Impact the Efficacy of Cetuximab plus Chemotherapy in mCRC: A Retrospective Biomarker Analysis. <i>Journal of Oncology</i> , 2018, 2018, 1-14.	1.3	12
27	Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 3569-3577.	1.9	100
28	Differences in clinical characteristics and mutational pattern between synchronous and metachronous colorectal liver metastases. <i>Cancer Management and Research</i> , 2018, Volume 10, 2871-2881.	1.9	11
29	Low tumor infiltrating mast cell density confers prognostic benefit and reflects immunoactivation in colorectal cancer. <i>International Journal of Cancer</i> , 2018, 143, 2271-2280.	5.1	62
30	Ratio of M2 tumor-associated macrophages as a better prognostic and predictive biomarkers for postoperative adjuvant chemotherapy in patients with stage II colon cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15582-e15582.	1.6	1
31	Tumor-associated macrophages as predictive biomarkers for postoperative adjuvant chemotherapy in patients with stage II colon cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 620-620.	1.6	0
32	Tumor purity as a prognostic factor in colon cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15646-e15646.	1.6	0
33	Patients with RAS wild-type right-sided unresectable liver-confined mCRC also benefit from cetuximab plus chemotherapy in first-line treatment. <i>American Journal of Cancer Research</i> , 2018, 8, 2337-2345.	1.4	5
34	Early activated hepatic stellate cell-derived paracrine molecules modulate acute liver injury and regeneration. <i>Laboratory Investigation</i> , 2017, 97, 318-328.	3.7	26
35	Bone Marrow Myeloid Cells Regulate Myeloid-Biased Hematopoietic Stem Cells via a Histamine-Dependent Feedback Loop. <i>Cell Stem Cell</i> , 2017, 21, 747-760.e7.	11.1	68
36	CDKL1 promotes tumor proliferation and invasion in colorectal cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1613-1624.	2.0	13

#	ARTICLE	IF	CITATIONS
37	Robotic vs. laparoscopic vs. open abdominoperineal resection for low rectal cancer: Short-term outcomes of a single-center prospective randomized controlled trial.. Journal of Clinical Oncology, 2017, 35, 3603-3603.	1.6	4
38	Robotic procedure versus open surgery for simultaneous resection of colorectal cancer with liver metastases: Short-term outcomes of a randomized controlled study.. Journal of Clinical Oncology, 2017, 35, 3575-3575.	1.6	5
39	Randomized Controlled Trial of Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer. Annals of Surgery, 2016, 263, 434-439.	4.2	25
40	Gastrin and upper GI cancers. Current Opinion in Pharmacology, 2016, 31, 31-37.	3.5	52
41	Ribosomal protein S15A promotes malignant transformation and predicts poor outcome in colorectal cancer through misregulation of p53 signaling pathway. International Journal of Oncology, 2016, 48, 1628-1638.	3.3	32
42	Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort study. Oncotarget, 2016, 7, 11380-11396.	1.8	12
43	Searching for predictive biomarkers on the efficacy of cetuximab plus chemotherapy for patients with unresectable colorectal liver-limited metastases: An expended biomarker analysis based on BELIEF study.. Journal of Clinical Oncology, 2016, 34, e15079-e15079.	1.6	0
44	A specific KRAS codon 13 mutation is an independent predictor for colorectal cancer metachronous distant metastases. American Journal of Cancer Research, 2015, 5, 674-88.	1.4	6
45	Isolation and culture of hepatic stellate cells from mouse liver. Acta Biochimica Et Biophysica Sinica, 2014, 46, 291-298.	2.0	57
46	Impact of early tumor shrinkage on clinical outcome in KRAS wild-type colorectal liver-limited metastases treated with cetuximab plus chemotherapy: Lessons from a randomized controlled trial.. Journal of Clinical Oncology, 2013, 31, 3610-3610.	1.6	0